Jakob Dupont
Overview
Explore the profile of Jakob Dupont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeNardo D, Galkin A, Dupont J, Zhou L, Bendell J
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34452928
Resistance to immune checkpoint inhibitors (ICI) and other anticancer therapies is often associated with the accumulation of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME)....
2.
Hu Z, Bendell J, Bullock A, Loconte N, Hatoum H, Ritch P, et al.
Cancer Med
. 2019 Jul;
8(11):5148-5157.
PMID: 31347292
Purpose: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients And Methods: Aphase 2, randomized,...
3.
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
Smith D, Chugh R, Patnaik A, Papadopoulos K, Wang M, Kapoun A, et al.
Invest New Drugs
. 2018 Dec;
37(4):722-730.
PMID: 30591982
Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via...
4.
Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, et al.
Clin Cancer Res
. 2017 Sep;
23(24):7490-7497.
PMID: 28954784
Wnt signaling is implicated in tumor cell dedifferentiation and cancer stem cell function. Ipafricept (OMP-54F28) is a first-in-class recombinant fusion protein with the extracellular part of human frizzled 8 receptor...
5.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, et al.
J Clin Oncol
. 2016 Nov;
35(3):352-360.
PMID: 27870570
Purpose Adenoid cystic carcinomas (ACCs) represent a heterogeneous group of chemotherapy refractory tumors, with a subset demonstrating an aggressive phenotype. We investigated the molecular underpinnings of this phenotype and assessed...
6.
Smith D, Eisenberg P, Manikhas G, Chugh R, Gubens M, Stagg R, et al.
Clin Cancer Res
. 2014 Oct;
20(24):6295-303.
PMID: 25324140
Purpose: This phase I trial evaluated the safety, pharmacokinetics, and pharmacodynamics of demcizumab (OMP-21M18), a humanized IgG2 mAb targeting the Notch ligand DLL4 in adult patients with advanced malignancies. Experimental...
7.
Konner J, Grisham R, Park J, OConnor O, Cropp G, Johnson R, et al.
Invest New Drugs
. 2011 Nov;
30(6):2294-302.
PMID: 22072399
Purpose: To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma. Patients And Methods: Patients were treated weekly for 3...
8.
Wang-Gillam A, Tew W, Rothenberg M, Dupont J, Cooper W, Sternas L, et al.
Invest New Drugs
. 2011 Oct;
30(5):1958-61.
PMID: 22002018
Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study...
9.
Zang X, Sullivan P, Soslow R, Waitz R, Reuter V, Wilton A, et al.
Mod Pathol
. 2010 May;
23(8):1104-12.
PMID: 20495537
B7-H3 and B7x are members of the B7 family of immune regulatory ligands that are thought to attenuate peripheral immune responses through co-inhibition. Previous studies have correlated their overexpression with...
10.
Tew W, Gordon M, Murren J, Dupont J, Pezzulli S, Aghajanian C, et al.
Clin Cancer Res
. 2009 Dec;
16(1):358-66.
PMID: 20028764
Purpose: To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent. Experimental...